- Home
- NRIX vs MEGI Comparison
NRIX vs MEGI Comparison
Compare NRIX & MEGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- MEGI
- Stock Information
- Founded
- NRIX 2009
- MEGI 2021
- Country
- NRIX United States
- MEGI United States
- Employees
- NRIX N/A
- MEGI N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- MEGI Investment Managers
- Sector
- NRIX Health Care
- MEGI Finance
- Exchange
- NRIX Nasdaq
- MEGI Nasdaq
- Market Cap
- NRIX 750.4M
- MEGI 774.5M
- IPO Year
- NRIX 2020
- MEGI N/A
- Fundamental
- Price
- NRIX $12.78
- MEGI $14.24
- Analyst Decision
- NRIX Strong Buy
- MEGI
- Analyst Count
- NRIX 14
- MEGI 0
- Target Price
- NRIX $26.29
- MEGI N/A
- AVG Volume (30 Days)
- NRIX 1.7M
- MEGI 178.0K
- Earning Date
- NRIX 10-09-2025
- MEGI 01-01-0001
- Dividend Yield
- NRIX N/A
- MEGI 11.40%
- EPS Growth
- NRIX N/A
- MEGI N/A
- EPS
- NRIX N/A
- MEGI N/A
- Revenue
- NRIX $83,687,000.00
- MEGI N/A
- Revenue This Year
- NRIX $58.48
- MEGI N/A
- Revenue Next Year
- NRIX N/A
- MEGI N/A
- P/E Ratio
- NRIX N/A
- MEGI N/A
- Revenue Growth
- NRIX 48.32
- MEGI N/A
- 52 Week Low
- NRIX $8.18
- MEGI $10.63
- 52 Week High
- NRIX $29.56
- MEGI $14.89
- Technical
- Relative Strength Index (RSI)
- NRIX 64.49
- MEGI 34.86
- Support Level
- NRIX $11.37
- MEGI $14.76
- Resistance Level
- NRIX $12.45
- MEGI $15.05
- Average True Range (ATR)
- NRIX 0.75
- MEGI 0.24
- MACD
- NRIX 0.20
- MEGI -0.06
- Stochastic Oscillator
- NRIX 84.06
- MEGI 6.29
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund
NYLI CBRE Global Infrastructure Megatrends Term Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It is focused on the investment megatrends of decarbonization, digital transformation and asset modernization, which are reshaping the demand for infrastructure assets and driving income and growth potential.